Richard F. Spark, M.D.; James C. Melby, M.D.
This content is PDF only. Please click on the PDF icon to access.
The demonstration of low plasma renin activity (PRA) and increased aldoestrone secretory rate (ASR) may not be sufficient to distinguish primary aldosteronism due to an aldosterone secretory adenoma from secondary aldosteronism associated with renovascular and accelerated hypertension. Since aldosterone hypersecretion is responsible for the hypertension in primary aldosteronism and is not causative in secondary aldosteronism, antagonism of aldosterone action by spironolactone should relieve hypertension only in primary aldosteronism. Response to spironolactone given in high dose (400 mg/day) for 3 to 5 weeks to 42 patients with elevated ASR and hypertension was as follows:
Serum electrolyte abnormalities were corrected in both
Spark RF, Melby JC. Aldosteronism in Hypertension: Spironolactone Response Test.. Ann Intern Med. 1968;68:1162–1163. doi: https://doi.org/10.7326/0003-4819-68-5-1162_3
Download citation file:
Published: Ann Intern Med. 1968;68(5):1162-1163.
Adrenal Disorders, Cardiology, Coronary Risk Factors, Endocrine and Metabolism, Hypertension.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use